Full access

Letters to the Editor

Published Online: 1 March 2019

Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine

Gerard Sanacora, M.D., Ph.D. [email protected]Authors Info & Affiliations

Publication: American Journal of Psychiatry

Volume 176, Number 3

https://doi.org/10.1176/appi.ajp.2018.18091061

PDF/EPUB OtherFormats

Formats available

You can view the full content in the following formats:

View PDF/EPUB View Full Text

Information & Authors

Information

Published In

American Journal of Psychiatry

Volume 176 • Number 3 • March 01, 2019

Pages: 249

PubMed: 30818992

History

Accepted: 15 October 2018

Published online: 1 March 2019

Published in print: March 01, 2019

Authors

Details

Gerard Sanacora, M.D., Ph.D. [email protected]

Department of Psychiatry, Yale University School of Medicine, and Yale–New Haven Health System, New Haven, Conn.

View all articles by this author

Notes

Send correspondence to Dr. Sanacora ([email protected]).

Funding Information

Yale-New Haven Health System:

CT Department of Mental Health and Addiction Services:

Supported by the Connecticut Department of Mental Health and Addiction Services, Yale–New Haven Health System, and the VA.Dr. Sanacora has received consulting fees from Alkermes, Allergan, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Hoffmann–La Roche, Intra-Cellular Therapies, Janssen, Merck, Naurex, Navitor Pharmaceuticals, Novartis, Noven Pharmaceuticals, Otsuka, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics. He has also received research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffmann–La Roche, Merck, Naurex, and Servier Pharmaceuticals. No-cost medication was provided to Dr. Sanacora for an NIH-sponsored study by Sanofi-Aventis. In addition, he holds shares in Biohaven Pharmaceuticals Holding Company and is a co-inventor on the patent “Glutamate agents in the treatment of mental disorders” (patent 8778979).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format	RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks
Direct importt
Citation style
Style

Copy to clipboard
Tips for downloading citations

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR^® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine

Formats available